DoMore Diagnostics

DoMore Diagnostics is an Oslo-based innovator applying artificial intelligence to digital pathology to improve cancer diagnostics and treatment personalization. The company's flagship product, Histotype Px® Colorectal, is a prognostic biomarker that analyzes standard H&E-stained tissue slides to predict survival and adjuvant chemotherapy benefit in stage II/III colon cancer, with clinical validation data presented at major oncology conferences. Backed by prominent research institutions and recent non-dilutive EIC Accelerator funding of up to €10 million, the company is positioned to advance its AI platform towards clinical adoption and expand into other cancer indications. Its mission is to provide objective, precise tools that enable more informed treatment decisions, improve patient outcomes, and reduce healthcare costs.

AI-based digital pathology platform that analyzes standard H&E-stained tissue slides to extract prognostic and predictive biomarkers for cancer treatment guidance.

DoMore competes in the growing AI-digital pathology space with companies like Paige, PathAI, and Ibex Medical Analytics, which also develop algorithms for cancer detection and classification. Its specific focus on prognostic stratification and chemotherapy benefit prediction in colorectal cancer provides a differentiated niche, but it must contend with these broader platforms and potential future entries from large diagnostic firms like Roche or Philips.